Table 2.

Clinical profile of renal transplant (RT) recipients with post-transplant renal cell carcinoma (RCC)

Age range (years) (sex)	Duration of dialysis prior to RT (months)	Post-RT RCC screening	Stage	Histology	Site of RCC	Treatment	Graft function	Survival
60–69 (F)	12	Yes	I	Clear cell	Allograft	Transplant nephrectomy	Failed	Alive
50–59 (M)	6	Yes	I	Papillary	Native	Nephrectomy	Failed	Alive
40–49 (M)	72	Yes	I	Chromophobe	Native	Nephrectomy	Preserved	Alive
10–19 (M)	1	No	I	Papillary	Allograft	Transplant nephrectomy	Failed	Alive
80–89 (M)	12	Yes	I	Papillary	Native	Percutaneous cryotherapy	Preserved	Alive
50–59 (F)	36	Yes	I	Clear cell	Native	Nephrectomy	Preserved	Alive
60–69 (F)	84	Yes	I	Clear cell	Allograft	Transplant nephrectomy	Failed	Alive
40–49 (M)	72	No	IV	Clear cell	Native	Immunotherapy	Failed	Died from metastatic RCC
60–69 (M)	72	Yes	II	Clear cell	Native	Nephrectomy	Failed	Alive
30–39 (M)	24	Yes	I	Clear cell	Native	Nephrectomy	Failed	Alive
60–69 (M)	60	Yes	I	Clear cell	Native	Nephrectomy	Preserved	Alive
50–59 (M)	48	No	I	Clear cell	Allograft	Transplant nephrectomy	Failed	Died in 2021 from COVID-19
60–69 (F)	72	Yes	I	Clear cell	Allograft	Cryotherapy	Brief dialysis support followed by renal recovery	Alive
20–29 (M)	36	No	III	Clear cell	Native	Nephrectomy	Failed	Alive
60–69 (M)	24	Yes	I	Clear cell	Native	Nephrectomy	Failed	Died from gastric cancer
30–39 (M)	4	No	IV	Papillary	Allograft	Transplant nephrectomy with pelvic lymph nephrectomy	Preserved	Died from metastatic RCC
40–49 (M)	120	Yes	I	Clear cell	Allograft	Transplant nephrectomy	Failed	Died in 2018 from sepsis
60–69 (M)	36	No	III	Clear cell	Native	Nephrectomy	Preserved	Alive
50–59 (F)	12	No	I	Clear cell	Allograft	Transplant nephrectomy	Failed	Alive
50–59 (M)	72	No	IV	Clear cell	Native	Sunitinib	Preserved	Died in 2012 from metastatic RCC